Epigenomics Q2 Revenues Rise 18 Percent; CEO Says FDA Approval of its Colorectal Screening Test 'Very Likely' | GenomeWeb

NEW YORK (GenomeWeb) – Epigenomics today said that its second quarter revenues rose 18 percent year over year.

The company's revenues for the three months ended June 30 reached €405,000 ($541,000), compared to €343,000 in Q2 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.